StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment
Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...
Sinotau Pharma Files for HK IPO Focused on Radiopharmaceutical Pipeline
China-based Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a leader in nuclear medicine (radiopharmaceuticals), announced...
Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC
Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech...
Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment
Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s...
Harbin Gloria Partners with Kowa Pharmaceuticals to Promote Parmodia in China
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced last week that it has entered...
BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...
Ayshealth Technology Secures Angel Funding for Artificial Blood Vessel Research
Guangzhou-based Ayshealth Technology, a developer of tissue repair and reconstruction devices, has reportedly secured an...
Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic...
Kexing Pharma’s GB18 Receives NMPA Approval for Cancer Cachexia Trial
China-based Kexing Pharmaceutical (SHA: 688136) announced that it has received approval from the National Medical...
Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs
US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-4712 Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from the...
Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts
Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase...
Fosun Pharma’s HLX22 Granted Orphan Drug Designation by EU Commission
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
UCB Launches Rystiggo in China for Generalized Myasthenia Gravis
Belgium-based biopharma UCB (EBR: UCB) announced the official market launch of Rystiggo (rozanolixizumab) in China....
Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...
Hainan Introduces New Pricing Rules for Digital Therapeutics Effective June 1
The Hainan provincial healthcare security administration and health commission bureaus jointly issued the “Notice on...
Kanghong Pharma Wins NMPA Approval for KH617 in Glioblastoma Trial
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...
Shandong Kanghua Biotechnology Announces IPO Plans on Beijing Stock Exchange
China-based Shandong Kanghua Biotechnology Co., Ltd., a developer of in vitro diagnostic (IVD) reagents, has...
Salubris Pharma Inks Licensing Deal for Gowell’s GW906 in Greater China
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced a licensing agreement with compatriot firm...
Walvax Biotechnology Secures Exclusive Rights to Notitia’s Gut Microbiota Therapy
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced an exclusive sublicense agreement with US-based Notitia...